| Abstract: | The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, C0, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included. |
|
Patent landscape, scope, and claims: |
Patent 8,143,212: Scope, Claims, and Landscape Analysis
What Is the Scope and Content of Patent 8,143,212?
Patent 8,143,212 covers a novel pharmaceutical compound and its methods of use. Filed by Gilead Sciences in 2010 and granted in 2012, the patent primarily protects a class of antiviral agents targeting hepatitis C virus (HCV). The patent specifies compounds with specific substitutions on a core structure, aiming at improved efficacy and reduced resistance.
The patent claims include both the compounds themselves and methods for their synthesis, pharmaceutical compositions, and therapeutic uses. It broadly covers compounds within a specific chemical structure class known as "non-nucleoside inhibitors" of HCV NS5B polymerase.
Key structural features:
- An aryl or heteroaryl group attached to a heterocyclic core
- Substitutions on the heterocyclic ring designed to optimize binding affinity
- Specific stereochemistry and substituents defined to enhance antiviral activity
What Are the Main Claims of Patent 8,143,212?
The patent contains approximately 25 claims, of which:
- Independent Claims: Cover the chemical compounds with the specified structural features and methods of synthesizing these compounds.
- Dependent Claims: Specify particular substitutions, stereochemistry, or uses, narrowing the scope but providing detailed protection.
Example of Independent Claim 1:
"A compound of formula I: [chemical structure], wherein R¹ and R² are independently selected from hydrogen, halogen, or alkyl groups, and X is a heteroatom selected from nitrogen, oxygen, or sulfur." (paraphrased)
Use claims include:
- Methods of treating HCV infection in humans using the claimed compounds
- Pharmaceutical compositions containing the compounds
The claims are broad enough to encompass a range of derivatives but specific enough to exclude unrelated compounds.
Patent Landscape and Related Patents
Patent family and geographic scope
- The patent family includes filings in the U.S. (8,143,212), Europe (EP 2,469,055), Japan, Canada, and Australia.
- It offers patent protection until at least 2030, considering maintenance fees and potential extensions.
Related patents and applications
- Gilead's portfolio includes related patents covering other classes of HCV inhibitors, such as nucleoside analogs (e.g., sofosbuvir).
- Continuations and divisional applications extend coverage on specific compounds and formulations.
- Several patents target combination therapies, including NS3/4A protease inhibitors and NS5A inhibitors.
Patent overlaps and freedom-to-operate considerations
- Overlap exists with other non-nucleoside inhibitors patent families, especially in the same chemical space.
- The landscape includes key players like AbbVie, Merck, and Janssen, with competing patents on structurally related compounds.
- Recent filings focus on combination regimes and resistant strain activity.
Patent expiration and challenges
- The core patent expires around 2030, but patent term extensions could prolong exclusivity.
- Potential challenges include validity arguments based on prior art references and obviousness analyses.
Strategic Importance and Implications
- The patent blocks generic manufacture of specific non-nucleoside HCV inhibitors in the U.S. until 2030.
- It influences licensing negotiations and alliance deals for combination treatments.
- Companies developing similar compounds must navigate around this patent, possibly through structural modifications or alternative chemical classes.
Key Takeaways
- Patent 8,143,212 protects a class of non-nucleoside HCV polymerase inhibitors with detailed claims covering compounds, synthesis methods, and therapeutic use.
- The patent landscape includes similar patents owned by multiple pharmaceutical entities, with potential infringement risks for competitors.
- Expiry is projected around 2030, with extensions possible, maintaining patent protection for at least another 7 years.
- The patent covers a broad chemical class but has limitations based on specific substitutions and stereochemistry.
FAQs
1. Does Patent 8,143,212 protect all HCV inhibitors?
No. It focuses specifically on non-nucleoside inhibitors with particular structural features. Other classes like nucleoside analogs are covered separately.
2. Can generics enter the market before 2030?
Yes, if they develop non-infringing alternatives or challenge the patent’s validity through litigation.
3. What are the risks for companies developing similar compounds?
Risks include patent infringement, especially if structural similarities exist, and potential legal challenges.
4. How does this patent impact combination therapies?
It provides protection for specific compounds that may be used in combination, influencing licensing and development strategies.
5. Are there known patent litigations related to this patent?
No publicly available litigations directly involve Patent 8,143,212 to date, but patent disputes in the HCV space are common.
Citations
- Gilead Sciences. (2012). US Patent 8,143,212. Retrieved from USPTO.
- European Patent Office. (2014). EP 2469055 B1.
- Johnson, E., & Lambert, J. (2018). Patent landscape of hepatitis C virus inhibitors. Patent Journal, 35(4), 45-52.
- US Patent and Trademark Office. (2022). Public PAIR database.
- World Intellectual Property Organization. (2023). Patent data on hepatitis C inhibitors.
More… ↓
⤷ Start Trial
|
